Mini antibodies: biotech's next big thing?
Saturday, September 13, 2008 - 09:28
in Biology & Nature
LONDON (Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.